INVESTIGATOR PROTOCOL AGREEMENTInvestigator Protocol Agreement • March 22nd, 2024
Contract Type FiledMarch 22nd, 2024Title: A SU2C Catalyst® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab (Keytruda®) with vitamin D receptor agonist Paricalcitol (Zemplar®) in Patients with Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response (with no further improvement in their tumor)